127 related articles for article (PubMed ID: 18001701)
1. In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients.
Ferroni P; Martini F; D'Alessandro R; Magnapera A; Raparelli V; Scarno A; Davì G; Basili S; Guadagni F
Clin Chim Acta; 2008 Feb; 388(1-2):33-7. PubMed ID: 18001701
[TBL] [Abstract][Full Text] [Related]
2. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients.
Nadar S; Blann AD; Lip GY
Am J Hypertens; 2006 Sep; 19(9):970-7; discussion 978. PubMed ID: 16942942
[TBL] [Abstract][Full Text] [Related]
3. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
Nadar SK; Blann A; Beevers DG; Lip GY
J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572
[TBL] [Abstract][Full Text] [Related]
4. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy.
Nadar SK; Blann AD; Lip GY
J Intern Med; 2004 Oct; 256(4):331-7. PubMed ID: 15367176
[TBL] [Abstract][Full Text] [Related]
5. Soluble P-selectin as a marker of in vivo platelet activation.
Ferroni P; Martini F; Riondino S; La Farina F; Magnapera A; Ciatti F; Guadagni F
Clin Chim Acta; 2009 Jan; 399(1-2):88-91. PubMed ID: 18835553
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial.
Varughese GI; Patel JV; Tomson J; Blann AD; Hughes EA; Lip GY
J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113
[TBL] [Abstract][Full Text] [Related]
7. Relationship of homocysteine to markers of platelet and endothelial activation in "high risk" hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Martin SC; Felmeden DC; Blann AD; Beevers GD; Lip GY
Int J Cardiol; 2004 Apr; 94(2-3):293-300. PubMed ID: 15093996
[TBL] [Abstract][Full Text] [Related]
8. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Nadar SK; Blann AD; Kamath S; Beevers DG; Lip GY
J Am Coll Cardiol; 2004 Jul; 44(2):415-22. PubMed ID: 15261941
[TBL] [Abstract][Full Text] [Related]
9. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria.
Ferroni P; Guagnano MT; Falco A; Paoletti V; Manigrasso MR; Michetti N; Santilli F; Guadagni F; Basili S; Davì G
Clin Sci (Lond); 2008 Mar; 114(6):449-55. PubMed ID: 17988217
[TBL] [Abstract][Full Text] [Related]
10. Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease.
Ferroni P; Basili S; Martini F; Vieri M; Labbadia G; Cordova C; Alessandri C; Gazzaniga PP
J Investig Med; 2000 Jan; 48(1):21-7. PubMed ID: 10695266
[TBL] [Abstract][Full Text] [Related]
11. Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.
Caine GJ; Harris AL; Christodoulos K; Lip GY; Blann AD
Cancer Lett; 2005 Mar; 219(2):163-7. PubMed ID: 15723715
[TBL] [Abstract][Full Text] [Related]
12. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions.
Riondino S; Martini F; La Farina F; Spila A; Guadagni F; Ferroni P
Clin Biochem; 2010 May; 43(7-8):666-70. PubMed ID: 20060822
[TBL] [Abstract][Full Text] [Related]
13. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol.
Celik T; Yuksel UC; Iyisoy A; Kursaklioglu H; Ozcan O; Kilic S; Ozmen N; Isik E
Int J Cardiol; 2007 Mar; 116(2):206-11. PubMed ID: 16822563
[TBL] [Abstract][Full Text] [Related]
14. The origin of P-selectin as a circulating plasma protein.
Fijnheer R; Frijns CJ; Korteweg J; Rommes H; Peters JH; Sixma JJ; Nieuwenhuis HK
Thromb Haemost; 1997 Jun; 77(6):1081-5. PubMed ID: 9241736
[TBL] [Abstract][Full Text] [Related]
15. Plasma indices of endothelial and platelet activation in Rheumatoid Disease: relationship to cardiovascular co-morbidity.
Bhatia GS; Sosin MD; Patel JV; Grindulis KA; Khattak FH; Davis RC; Lip GY
Int J Cardiol; 2009 May; 134(1):97-103. PubMed ID: 18501982
[TBL] [Abstract][Full Text] [Related]
16. Endothelium and angiogenesis in white coat hypertension.
Karter Y; Aydin S; Curgunlu A; Uzun H; Ertürk N; Vehid S; Kutlu A; Simsek G; Yücel R; Arat A; Ozturk E; Erdine S
J Hum Hypertens; 2004 Nov; 18(11):809-14. PubMed ID: 15215878
[TBL] [Abstract][Full Text] [Related]
17. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension.
Tsai WC; Li YH; Huang YY; Lin CC; Chao TH; Chen JH
Clin Sci (Lond); 2005 Jul; 109(1):39-43. PubMed ID: 15740459
[TBL] [Abstract][Full Text] [Related]
18. Haemorheological, platelet and endothelial indices in relation to global measures of cardiovascular risk in hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Felmeden DC; Blann AD; Lip GY
J Intern Med; 2007 Jan; 261(1):82-90. PubMed ID: 17222171
[TBL] [Abstract][Full Text] [Related]
19. Soluble P selectin levels in chronic liver disease: relationship to disease severity.
Vardareli E; Saricam T; Demirustu C; Gulbas Z
Hepatogastroenterology; 2007 Mar; 54(74):466-9. PubMed ID: 17523300
[TBL] [Abstract][Full Text] [Related]
20. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Undas A; Stepień E; Branicka A; Wołkow P; Zmudka K; Tracz W
Kardiol Pol; 2009 Jun; 67(6):591-8. PubMed ID: 19618315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
